Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer: results from the MaTox project.
Hans-Jürgen HurtzHans TeschThomas GöhlerUlrich HutzschenreuterJohanna HardeLisa KruggelMartina JänickeNorbert Marschnernull nullPublished in: Breast cancer research and treatment (2017)
Our data show that most patients with breast cancer have persistent impairments negatively influencing their daily life even 3 years after treatment. Furthermore, we highlight areas requiring special attention in follow-up care.